abs359.txt	objective		older	patients	with	cancer	suffer	from	chemotherapy-related	toxicitiesmore	frequently	than	younger	as	novel	agents	are	being	used	morecommonly	in	chronic	lymphocytic	leukemia	(cll)	and	non-hodgkin	lymphoma	(nhl)	toxicities	of	these	have	not	been	well	studied	further	impact	on	outcomes	the	elderly	is	unknown	this	studyaimed	to	answer	both	questions	methods	we	reviewed	14	alliance	for	clinical	trials	oncologytrials	that	enrolled	cll	and/or	nhl	between	2004-2014	toxicity	wasassessed	per	nci-ctcae	(version	3-5)	probabilities	experiencing	gradethree	or	four	hematologic	non-hematologic	were	modeled	afunction	disease-related	factors	using	logistic	regression	results	1199	(409	age	â‰¥	65	790	<	65)	analyzed	438	receivedonly	biologic	therapy	(145	293	761	receivedbiologic	+	chemotherapy	(264	497	odds	grade	three	orfour	[odds	ratio	(or)	1	70	p	=	0	009	95%	ci	(1	57-1	84)]	andnon-hematologic	[or	47	022	39-1	55)]	wereincreased	fournon-hematologic	89	017	64-2	17)]	olderpatients	associatedwith	inferior	os	pfs	[hr	3	006	ci(2	25-4	39)	06	011	(2	10-4	45)	pfs]	though	notin	a	prognostic	model	predicting	was	alsodeveloped	conclusions	year	encounter	more	thanyounger	even	when	treated	development	ofgrade	lead	butnot
